{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,20]],"date-time":"2026-06-20T04:54:41Z","timestamp":1781931281022,"version":"3.54.5"},"reference-count":60,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"6","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2018,11]]},"abstract":"<jats:sec>\n            <jats:title>Purpose of review<\/jats:title>\n            <jats:p>The aim of this study was to provide the most recent evidence on clinical utility of myositis-specific autoantibodies (MSAs) in the management of patients with myositis.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Recent findings<\/jats:title>\n            <jats:p>In the last few years, several evidences have emerged on the clinical and pathogenetic role of established and novel MSA. Antisynthetase antibodies represent a reliable biomarker for pulmonary involvement also in patients with connective tissue diseases other than myositis. Antisignal recognition particle and antihydroxy-3-methylglutaryl coenzyme A reductase autoantibodies are able to induce complement-dependent muscle damage. Dermatomyositis-specific antibodies are useful indicators of clinical diversity. The pivotal role of antitranscription intermediary factor 1\u03b3 autoimmune response in adult-age paraneoplastic dermatomyositis has been further asserted. AnticN1A and antifour-and-a-half LIM protein 1 antibodies are newly conceived myositis-related antibody specificities, which can contribute to patients\u2019 stratification into more homogeneous groups.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Summary<\/jats:title>\n            <jats:p>Distinct autoantibody-associated clinical phenotypes can be predicted by extended MSA testing in serum. Standardization and validation of MSA laboratory detection methods is strongly recommended for better supporting myositis diagnosis, management and prognosis definition.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/bor.0000000000000548","type":"journal-article","created":{"date-parts":[[2018,9,26]],"date-time":"2018-09-26T22:05:34Z","timestamp":1537999534000},"page":"614-622","source":"Crossref","is-referenced-by-count":48,"title":["New insights in myositis-specific autoantibodies"],"prefix":"10.1097","volume":"30","author":[{"given":"Anna","family":"Ghirardello","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Doria","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-20230901","doi-asserted-by":"crossref","first-page":"e172","DOI":"10.1212\/NXI.0000000000000172","article-title":"Myositis-specific autoantibodies are specific for myositis compared to genetic muscle disease","volume":"2","author":"Mammen","year":"2015","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"key":"R2-20230901","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1038\/nrrheum.2017.1","article-title":"New tools for diagnosis and therapy","volume":"13","author":"Lundberg","year":"2017","journal-title":"Nat Rev Rheumatol"},{"key":"R3-20230901","doi-asserted-by":"crossref","first-page":"1164","DOI":"10.1111\/jdv.14759","article-title":"Distinctive cutaneous and systemic features associated with specific antimyositis antibodies in adults with dermatomyositis: a prospective multicentric study of 117 patients","volume":"32","author":"Best","year":"2018","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"R4-20230901","first-page":"176","article-title":"Autoantibody testing in patients with myositis: clinical accuracy of a multiparametric line immunoassay","volume":"35","author":"Ghirardello","year":"2017","journal-title":"Clin Exp Rheumatol"},{"key":"R5-20230901","doi-asserted-by":"crossref","first-page":"712","DOI":"10.1093\/rheumatology\/kex458","article-title":"Presence of antieukaryotic initiation factor-2B, anti-RuvBL1\/2 and antisynthetase antibodies in patients with antinuclear antibody negative systemic sclerosis","volume":"57","author":"Pauling","year":"2018","journal-title":"Rheumatology (Oxford)"},{"key":"R6-20230901","doi-asserted-by":"crossref","first-page":"2485","DOI":"10.1093\/brain\/awv192","article-title":"Anti-Jo-1 antibody-positive patients show a characteristic necrotizing perifascicular myositis","volume":"138","author":"Mescam-Mancini","year":"2015","journal-title":"Brain"},{"key":"R7-20230901","doi-asserted-by":"crossref","first-page":"612","DOI":"10.1097\/BOR.0000000000000434","article-title":"Clinical spectrum of anti-Jo-1-associated disease","volume":"29","author":"Monti","year":"2017","journal-title":"Curr Opin Rheumatol"},{"key":"R8-20230901","first-page":"44","article-title":"Timing of onset affects arthritis presentation pattern in antisynthetase syndrome","volume":"36","author":"Gonz\u00e1lez-Gay","year":"2018","journal-title":"Clin Exp Rheumatol"},{"key":"R9-20230901","first-page":"1264","article-title":"The utility of comprehensive autoantibody testing to differentiate connective tissue disease associated and idiopathic interstitial lung disease subgroup cases","volume":"56","author":"Cotton","year":"2017","journal-title":"Rheumatology (Oxford)"},{"key":"R10-20230901","doi-asserted-by":"crossref","first-page":"999","DOI":"10.1093\/rheumatology\/kex021","article-title":"A longitudinal cohort study of the antisynthetase syndrome: increased severity of interstitial lung disease in black patients and patients with anti-PL7 and anti-PL12 autoantibodies","volume":"56","author":"Pinal-Fernandez","year":"2017","journal-title":"Rheumatology (Oxford)"},{"key":"R11-20230901","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1038\/nrrheum.2018.56","article-title":"Autoantibodies in myositis","volume":"14","author":"McHugh","year":"2018","journal-title":"Nat Rev Rheumatol"},{"key":"R12-20230901","doi-asserted-by":"crossref","first-page":"e507","DOI":"10.1212\/WNL.0000000000004923","article-title":"Necrosis in anti-SRP+ and anti-HMGCR+myopathies: role of autoantibodies and complement","volume":"90","author":"Allenbach","year":"2018","journal-title":"Neurology"},{"key":"R13-20230901","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1002\/acr.22920","article-title":"Longitudinal course of disease in a large cohort of myositis patients with autoantibodies recognizing the signal recognition particle","volume":"69","author":"Pinal-Fernandez","year":"2017","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"R14-20230901","first-page":"787","article-title":"More severe disease and slower recovery in younger patients with anti3-hydroxy-3-methylglutaryl-coenzyme A reductase-associated autoimmune myopathy","volume":"56","author":"Tiniakou","year":"2017","journal-title":"Rheumatology (Oxford)"},{"key":"R15-20230901","doi-asserted-by":"crossref","first-page":"1088","DOI":"10.1002\/acr.23113","article-title":"Association of anti3-hydroxy-3-methylglutaryl-Coenzyme A reductase autoantibodies with DRB1\u221707:01 and severe myositis in juvenile myositis patients","volume":"69","author":"Kishi","year":"2017","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"R16-20230901","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1016\/j.tibs.2015.09.006","article-title":"SUMOylation-mediated regulation of cell cycle progression and cancer","volume":"40","author":"Eifler","year":"2015","journal-title":"Trends Biochem Sci"},{"key":"R17-20230901","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1016\/j.jaut.2013.11.005","article-title":"The clinical features, diagnosis and classification of dermatomyositis","volume":"48-49","author":"Iaccarino","year":"2014","journal-title":"J Autoimmun"},{"key":"R18-20230901","doi-asserted-by":"crossref","first-page":"2806","DOI":"10.1002\/art.39753","article-title":"Muscle biopsy findings in combination with myositis-specific autoantibodies aid prediction of outcomes in juvenile dermatomyositis","volume":"68","author":"Deakin","year":"2016","journal-title":"Arthritis Rheumatol"},{"key":"R19-20230901","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1111\/cen3.12419","article-title":"Diagnosis of dermatomyositis: autoantibody profile and muscle pathology","volume":"8","author":"Uruha","year":"2017","journal-title":"Clin Exp Neuroimmunol"},{"key":"R20-20230901","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1007\/s11926-018-0733-5","article-title":"Dermatomyositis clinical and pathological phenotypes associated with myositis-specific autoantibodies","volume":"20","author":"Wolstencroft","year":"2018","journal-title":"Curr Rheumatol Rep"},{"key":"R21-20230901","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1016\/j.jdermsci.2016.09.013","article-title":"Enzyme-linked immunosorbent assays for detection of antitranscriptional intermediary factor-1 gamma and anti-Mi-2 autoantibodies in dermatomyositis","volume":"84","author":"Fujimoto","year":"2016","journal-title":"J Dermatol Sci"},{"key":"R22-20230901","doi-asserted-by":"crossref","first-page":"e233","DOI":"10.1111\/jdv.14754","article-title":"Four cases of anti-Mi-2 antibody-positive dermatomyositis: relationship between anti-Mi-2 antibody titre and disease severity and activity","volume":"32","author":"Matsuda","year":"2018","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"R23-20230901","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1093\/rheumatology\/kex413","article-title":"Tumour TIF1 mutations and loss of heterozygosity related to cancer-associated myositis","volume":"57","author":"Pinal-Fernandez","year":"2018","journal-title":"Rheumatology (Oxford)"},{"key":"R24-20230901","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1186\/s13075-017-1469-8","article-title":"Identification of multiple cancer-associated myositis-specific autoantibodies in idiopathic inflammatory myopathies: a large longitudinal cohort study","volume":"19","author":"Yang","year":"2017","journal-title":"Arthritis Res Ther"},{"key":"R25-20230901","article-title":"Strong correlation between cancer progression and antitranscription intermediary factor 1\u03b3 antibodies in dermatomyositis patients","author":"Ogawa-Momohara","year":"2018","journal-title":"Clin Exp Rheumatol"},{"key":"R26-20230901","doi-asserted-by":"crossref","first-page":"648","DOI":"10.1002\/acr.23325","article-title":"Association of antitranscription intermediary factor 1\u0263 with paraneoplastic rheumatic syndromes other than dermatomyositis","volume":"70","author":"Venalis","year":"2018","journal-title":"Arthritis Care Res"},{"key":"R27-20230901","doi-asserted-by":"crossref","first-page":"1771","DOI":"10.1002\/acr.23188","article-title":"Antinuclear matrix protein 2 autoantibodies and edema, muscle disease, and malignancy risk in dermatomyositis patients","volume":"69","author":"Albayda","year":"2017","journal-title":"Arthritis Care Res"},{"key":"R28-20230901","doi-asserted-by":"crossref","first-page":"1909","DOI":"10.1002\/acr.23210","article-title":"Cutaneous and systemic findings associated with nuclear matrix protein 2 antibodies in adult dermatomyositis patients","volume":"69","author":"Rogers","year":"2017","journal-title":"Arthritis Care Res"},{"key":"R29-20230901","doi-asserted-by":"crossref","first-page":"873","DOI":"10.1093\/rheumatology\/kex516","article-title":"Muscle ischaemia associated with NXP2 autoantibodies: a severe subtype of juvenile dermatomyositis","volume":"57","author":"Aouizerate","year":"2018","journal-title":"Rheumatology (Oxford)"},{"key":"R30-20230901","first-page":"303","article-title":"Calcinosis in poly-dermatomyositis: clinical and laboratory predictors and treatment options","volume":"35","author":"Fredi","year":"2017","journal-title":"Clin Exp Rheumatol"},{"key":"R31-20230901","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/j.trsl.2017.08.004","article-title":"The anticancer functions of RIG-I-like receptors, RIG-I and MDA5, and their applications in cancer therapy","volume":"190","author":"Wu","year":"2017","journal-title":"Transl Res"},{"key":"R32-20230901","doi-asserted-by":"crossref","first-page":"160","DOI":"10.21037\/atm.2017.03.94","article-title":"MDA5 autoantibody-another indicator of clinical diversity in dermatomyositis","volume":"5","author":"Sontheimer","year":"2017","journal-title":"Ann Transl Med"},{"key":"R33-20230901","doi-asserted-by":"crossref","first-page":"319","DOI":"10.3899\/jrheum.160682","article-title":"Antimelanoma differentiation-associated gene 5 antibody: expanding the clinical spectrum in North American patients with dermatomyositis","volume":"44","author":"Moghadam-Kia","year":"2017","journal-title":"J Rheumatol"},{"key":"R34-20230901","doi-asserted-by":"crossref","first-page":"76129","DOI":"10.18632\/oncotarget.19050","article-title":"Assessment of anti-MDA5 antibody as a diagnostic biomarker in patients with dermatomyositis-associated interstitial lung disease or rapidly progressive interstitial lung disease","volume":"8","author":"Li","year":"2017","journal-title":"Oncotarget"},{"key":"R35-20230901","doi-asserted-by":"crossref","first-page":"1293","DOI":"10.1007\/s00296-018-3991-7","article-title":"Rapidly progressive interstitial lung disease due to anti-MDA5 antibodies without skin involvement: a case report and literature review","volume":"38","author":"Gonz\u00e1lez-Moreno","year":"2018","journal-title":"Rheumatol Int"},{"key":"R36-20230901","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1111\/bjd.14882","article-title":"Antimelanoma differentiation-associated protein 5 antibody level is a novel tool for monitoring disease activity in rapidly progressive interstitial lung disease with dermatomyositis","volume":"176","author":"Matsushita","year":"2017","journal-title":"Br J Dermatol"},{"key":"R37-20230901","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1080\/14397595.2017.1318468","article-title":"Evaluation of clinical prognostic factors for interstitial pneumonia in anti-MDA5 antibody-positive dermatomyositis patients","volume":"28","author":"Fujiki","year":"2018","journal-title":"Mod Rheumatol"},{"key":"R38-20230901","doi-asserted-by":"crossref","first-page":"e0154285","DOI":"10.1371\/journal.pone.0154285","article-title":"Clinical utility of an enzyme-linked immunosorbent assay for detecting antimelanoma differentiation-associated gene 5 autoantibodies","volume":"11","author":"Sato","year":"2016","journal-title":"PLoS One"},{"key":"R39-20230901","doi-asserted-by":"crossref","first-page":"862","DOI":"10.1136\/annrheumdis-2016-210282","article-title":"Cytosolic 5\u2019-nucleotidase 1A autoantibody profile and clinical characteristics in inclusion body myositis","volume":"76","author":"Lilleker","year":"2017","journal-title":"Ann Rheum Dis"},{"key":"R40-20230901","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1002\/ana.24919","article-title":"Pathomechanisms of anticytosolic 5\u2019-nucleotidase 1A autoantibodies in sporadic inclusion body myositis","volume":"81","author":"Tawara","year":"2017","journal-title":"Ann Neurol"},{"key":"R41-20230901","doi-asserted-by":"crossref","first-page":"696","DOI":"10.1136\/annrheumdis-2014-206691","article-title":"Disease specificity of autoantibodies to cytosolic 5\u2019-nucleotidase 1A in sporadic inclusion body myositis versus known autoimmune diseases","volume":"75","author":"Herbert","year":"2016","journal-title":"Ann Rheum Dis"},{"key":"R42-20230901","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1002\/acr.22600","article-title":"Cytosolic 5\u2019-nucleotidase 1A as a target of circulating autoantibodies in autoimmune diseases","volume":"68","author":"Lloyd","year":"2016","journal-title":"Arthritis Care Res"},{"key":"R43-20230901","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.cca.2017.07.002","article-title":"Prevalence of anti-NT5C1A antibodies in Japanese patients with autoimmune rheumatic diseases in comparison with other patient cohorts","volume":"472","author":"Muro","year":"2017","journal-title":"Clin Chim Acta"},{"key":"R44-20230901","doi-asserted-by":"crossref","first-page":"714","DOI":"10.1136\/annrheumdis-2017-212436","article-title":"Anti-NT5C1A autoantibodies are associated with more severe disease in patients with juvenile myositis","volume":"77","author":"Yeker","year":"2018","journal-title":"Ann Rheum Dis"},{"key":"R45-20230901","doi-asserted-by":"crossref","first-page":"4612","DOI":"10.1172\/JCI81031","article-title":"Development of autoantibodies against muscle-specific FHL1 in severe inflammatory myopathies","volume":"125","author":"Albrecht","year":"2015","journal-title":"J Clin Invest"},{"key":"R46-20230901","doi-asserted-by":"crossref","first-page":"538","DOI":"10.1002\/ana.24902","article-title":"Pathogenic role of antisignal recognition protein and anti3-hydroxy-3-methilglutaryl-CoA reductase antibodies in necrotizing myopathies: myofiber atrophy and impairment of muscle regeneration in necrotizing autoimmune myopathies","volume":"81","author":"Arouche-Delaperche","year":"2017","journal-title":"Ann Neurol"},{"key":"R47-20230901","doi-asserted-by":"crossref","DOI":"10.1016\/j.semarthrit.2018.02.003","article-title":"The effect of cigarette smoking on the clinical and serological phenotypes of polymyositis and dermatomyositis","author":"Schiffenbauer","year":"2018","journal-title":"Semin Arthritis Rheum"},{"key":"R48-20230901","first-page":"75","article-title":"Triggers of inflammatory myopathy: insights into pathogenesis","volume":"25","author":"Adler","year":"2018","journal-title":"Discov Med"},{"key":"R49-20230901","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1080\/1744666X.2018.1440206","article-title":"Statin-induced myalgia and myositis: an update on pathogenesis and clinical recommendations","volume":"14","author":"Selva-O\u2019Callaghan","year":"2018","journal-title":"Expert Rev Clin Immunol"},{"key":"R50-20230901","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1016\/j.cyto.2014.10.012","article-title":"Interferons as components of the complex web of reactions sustaining inflammation in idiopathic inflammatory myopathies","volume":"74","author":"De Paepe","year":"2015","journal-title":"Cytokine"},{"key":"R51-20230901","doi-asserted-by":"crossref","first-page":"1224","DOI":"10.1111\/bjd.15006","article-title":"Correlation of cutaneous disease activity with type 1 interferon gene signature and interferon \u03b2 in dermatomyositis","volume":"176","author":"Huard","year":"2017","journal-title":"Br J Dermatol"},{"key":"R52-20230901","doi-asserted-by":"crossref","first-page":"8024","DOI":"10.1038\/s41598-017-08603-9","article-title":"Transcriptional profiling identifies differential expression of long noncoding RNAs in Jo-1 associated and inclusion body myositis","volume":"7","author":"Hamann","year":"2017","journal-title":"Sci Rep"},{"key":"R53-20230901","doi-asserted-by":"crossref","first-page":"1955","DOI":"10.1136\/annrheumdis-2017-211468","article-title":"2017 European League Against Rheumatism\/American College of Rheumatology classification criteria for adult and juvenile idiopathic inflammatory myopathies and their major subgroups","volume":"76","author":"Lunberg","year":"2017","journal-title":"Ann Rheum Dis"},{"key":"R54-20230901","article-title":"EULAR\/ACR classification criteria for adult and juvenile idiopathic inflammatory myopathies and their major subgroups: little emphasis on autoantibodies, why?","author":"Malaviya","year":"2017","journal-title":"Ann Rheum Dis"},{"key":"R55-20230901","article-title":"Detection of myositis-specific antibodies","author":"Vulsteke","year":"2018","journal-title":"Ann Rheum Dis"},{"key":"R56-20230901","doi-asserted-by":"crossref","first-page":"444","DOI":"10.3899\/jrheum.170258","article-title":"The antinuclear antibody test in the diagnosis of antisynthetase syndrome and other autoimmune myopathies","volume":"45","author":"Fritzler","year":"2018","journal-title":"J Rheumatol"},{"key":"R57-20230901","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1007\/s10067-016-3453-0","article-title":"Myositis-specific autoantibodies and their association with malignancy in Italian patients with polymyositis and dermatomyositis","volume":"36","author":"Ceribelli","year":"2017","journal-title":"Clin Rheumatol"},{"key":"R58-20230901","doi-asserted-by":"crossref","first-page":"983","DOI":"10.1016\/j.autrev.2016.07.023","article-title":"Anti-HMGCR antibodies as a biomarker for immune-mediated necrotizing myopathies: a history of statins and experience from a large international multicenter study","volume":"15","author":"Musset","year":"2016","journal-title":"Autoimmun Rev"},{"key":"R59-20230901","first-page":"1","article-title":"Improved quantification of a commercial enzyme-linked immunosorbent assay kit for measuring anti-MDA5 antibody","author":"Gono","year":"2018","journal-title":"Mod Rheumatol"},{"key":"R60-20230901","article-title":"Detection of myositis-specific antibodies: additional notes","author":"Mahler","year":"2018","journal-title":"Ann Rheum Dis"}],"container-title":["Current Opinion in Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/00002281-201811000-00014","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T01:17:32Z","timestamp":1693531052000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00002281-201811000-00014"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,11]]},"references-count":60,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2018]]}},"URL":"https:\/\/doi.org\/10.1097\/bor.0000000000000548","relation":{},"ISSN":["1040-8711","1531-6963"],"issn-type":[{"value":"1040-8711","type":"print"},{"value":"1531-6963","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,11]]}}}